Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1 clinical trials · Condition
◉ Watch Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
| Record | Firm | Date |
|---|---|---|
| Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer (NCT04274426) | AGO Research GmbH | 2021-10-13 |
Track Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.